Gleolan Brain Dye, imaging agent, helps neurosurgeons to see “high grade gliomas” during surgery. Learn about Gleolan.

We are looking for Glioblastoma (GBM) patients and their caregivers to participate in an important study on recurrent GBM.

PROSPECT is an open-label, Phase II study evaluating the efficacy, safety, and pharmacokinetics of an oral medicine called Tirabrutinib.

Imvax is conducting a new phase 2b clinical study, with a combination immunotherapy, for newly diagnosed patients with glioblastoma.

In decentralized Clinical Trials some or all trial-related procedures and compiling of patient and trial data takes place at locations/sites that are remote from the Principal Investigator.

This Month, I’d like to introduce you to the company, Reglagene, www.reglagene.com, a therapeutics company located in Tucson, AZ transforming tubulin targeting therapy for CNS diseases.

An advanced and highly precise form of radiation treatment is known as Proton Therapy (PT). PT minimizes damage to the surrounding tissue and risk of short- and long-term side effects because it allows radiation specialists to focus radiation directly into the tumor.

Targeted therapies are a type of cancer treatment that targets proteins that control how cancer cells grow, divide, and spread. They are the foundation of precision medicine. May12, 2023

The End Brain Cancer Initiative (EBCI) and I are once again thrilled to have this platform to increase patient education, awareness & outreach to the global brain tumor community and to the general public with the goal of increasing their direct access to top brain tumor specialists at brain tumor centers of excellence, multiple treatment options/diagnostics and clinical trials.

PDUFA, the Prescription Drug User Fee Acts, ensures the FDA retains its capacity to promote the health and well-being of all Americans for another five years.

If you have a solid tumor, you may benefit from an additional test called Next Generation Sequencing (NGS), which looks at the genes associated with cancer.

To create increased impact in the health and research industries and to help us reach our goal of growing to a $2M 501 (c)3 non-profit social enterprise organization, we are expanding our board of directors and are seeking new members.